<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="77402">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02095145</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2014-00695</org_study_id>
    <secondary_id>NCI-2014-00695</secondary_id>
    <secondary_id>CO11378</secondary_id>
    <secondary_id>UWI2013-00-01</secondary_id>
    <secondary_id>P30CA014520</secondary_id>
    <secondary_id>N01CN00033</secondary_id>
    <secondary_id>N01CN35153</secondary_id>
    <nct_id>NCT02095145</nct_id>
  </id_info>
  <brief_title>Pomegranate-Extract Pill in Preventing Tumor Growth in Patients With Localized Prostate Cancer Undergoing Active Surveillance</brief_title>
  <official_title>A Phase IIA Exploratory, Randomized, Placebo-Controlled Trial of Pomegranate Fruit Extract/Pomx in Subjects With Clinically Localized Prostate Cancer Undergoing Active Surveillance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized phase II trial studies pomegranate-extract pill in preventing tumor growth
      in patients with prostate cancer that is limited to a certain part of the body (localized),
      who have chosen observation as their treatment plan. The use of pomegranate-extract pill may
      slow disease progression in patients with localized prostate cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To determine the effect of pomegranate fruit extract (PFE) 1000 mg, taken daily for 1
      year, on the plasma levels of insulin-like growth factor (IGF-1) from baseline to end of
      study (52 weeks) in participants undergoing active surveillance (AS) for early stage
      prostate cancer.

      SECONDARY OBJECTIVES:

      I. To assess compliance with a once daily oral administration of PFE versus placebo over a
      52-week period of time.

      II. To assess the toxicity of PFE vs. placebo when taken daily for 52 weeks. III. To compare
      and correlate the modulation of the following biomarkers with response to PFE versus placebo
      on follow-up biopsy results performed at week 52 (or earlier if clinically indicated),
      including the presence or absence of tumor, the extent of tumor and Gleason scores; plasma
      biomarkers: Insulin-like growth factor 1/IGF binding protein 3 ratio (IGF-1/IGFBP-3 ratio);
      normal and abnormal prostate tissue biomarkers: prostate-specific antigen (PSA), IGFBP-3,
      apoptosis (TUNEL), proliferating cell nuclear antigen (PCNA), IGF-1 receptor (IGF-1R),
      8-hydroxy-2' -deoxyguanosine (8-OHdG) and androgen receptor.

      IV. Measure PFE constituents/metabolites in plasma and urine for evidence of accumulation
      (trough levels): ellagic acid, dimethyl ellagic acid, dimethyl ellagic acid glucuronide
      (DMEAG), urolithin A, urolithin A-glucuronide, urolithin B and urolithin B-glucuronide.

      V. Measure PSA doubling time (PSA DT) in serum, using the calculation provided on the
      Memorial Sloan Kettering Cancer Center website.

      VI. To assess the feasibility of cancer chemoprevention trials in a population of men
      undergoing active surveillance for prostate cancer.

      VII. Measurement of serum testosterone.

      OUTLINE: Patients are randomized to 1 of 2 groups.

      GROUP I: Patients receive pomegranate-extract pill orally (PO) once daily (QD) for 52 weeks.

      GROUP II: Patients receive placebo PO QD for 52 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2014</start_date>
  <primary_completion_date type="Anticipated">May 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Change in plasma IGF-1</measure>
    <time_frame>Baseline to 12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>The difference between the placebo group and the PFE group will be tested using a two-sample t-test with normalizing transformation if necessary or Wilcoxon rank-sum test.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Compliance, in terms of the number of pills missed</measure>
    <time_frame>Up to 1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Summarized by treatment arm with descriptive statistics, and tested for imbalance using Wilcoxon rank-sum test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events graded per Common Terminology Criteria for Adverse Events (CTCAE)</measure>
    <time_frame>Up to 1 year</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Patient toxicity throughout the study will be summarized in several ways; the presence or absence of any toxicity, worst CTCAE grade, and strongest investigator-defined relationship will all be examined and characterized by treatment arm, and analyzed appropriately (Wilcoxon rank-sum for ordinal data, Fisher's exact test for dichotomous data, and log rank test for time to event data).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in plasma biomarker levels</measure>
    <time_frame>Baseline to up to 1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Differences between the groups will be examined for the change from baseline with the appropriate tests; for dichotomous data Fisher's exact test will be used, for ordinal data Wilcoxon rank-sum test will be used, and for continuous data, and a two-sample t-test with normalizing transformation if necessary or Wilcoxon rank-sum test will be used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total serum PSA</measure>
    <time_frame>Up to 1 year</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in tissue biomarker levels</measure>
    <time_frame>Baseline to up to 1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Differences between the groups will be examined for the change from baseline with the appropriate tests; for dichotomous data Fisher's exact test will be used, for ordinal data Wilcoxon rank-sum test will be used, and for continuous data, and a two-sample t-test with normalizing transformation if necessary or Wilcoxon rank-sum test will be used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in levels of PFD constituents/metabolites</measure>
    <time_frame>Baseline to up to 1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Differences between the groups will be examined for the change from baseline with the appropriate tests; for dichotomous data Fisher's exact test will be used, for ordinal data Wilcoxon rank-sum test will be used, and for continuous data, and a two-sample t-test with normalizing transformation if necessary or Wilcoxon rank-sum test will be used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Gleason grade</measure>
    <time_frame>Baseline to 1 year</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in tumor volume on prostate biopsy</measure>
    <time_frame>Baseline to 1 year</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Stage I Prostate Cancer</condition>
  <condition>Stage IIA Prostate Cancer</condition>
  <condition>Stage IIB Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Group I (pomegranate-extract pill)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive pomegranate-extract pill PO QD for 52 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group II (placebo)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients receive placebo PO QD for 52 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pomegranate-extract pill</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Group I (pomegranate-extract pill)</arm_group_label>
    <other_name>POMx</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Group II (placebo)</arm_group_label>
    <other_name>PLCB</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Group I (pomegranate-extract pill)</arm_group_label>
    <arm_group_label>Group II (placebo)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Group I (pomegranate-extract pill)</arm_group_label>
    <arm_group_label>Group II (placebo)</arm_group_label>
    <other_name>pharmacological studies</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male patients must have had a standard-of-care biopsy within 3 months of the baseline
             study visit and must have been diagnosed with low-grade, clinically localized
             prostate cancer (Gleason score =&lt; 3+3, PSA, &lt; 10 ng/ml in patients &lt; 70 years of age,
             OR Gleason score =&lt; 3+4, PSA =&lt; 15 ng/ml in patients &gt;= 70 years of age); eligible
             participants will be those men who are able and willing to undergo AS with PSA
             monitoring, and a scheduled biopsy performed at the end of the study

          -  No concurrent treatment (hormonal, radiation or systemic chemotherapy) for prostate
             cancer during study enrollment is planned (unless participants meet criteria for
             disease progression, or otherwise demonstrate clinical evidence of prostate cancer
             progression such as: symptoms, physical exam findings, or radiologic findings which
             confirm disease progression)

          -  Eastern Cooperative Oncology Group (ECOG) performance status =&lt; 1

          -  White blood cells (WBC) &gt;= 3000/mm^3

          -  Platelets &gt;= 100,000 mm^3

          -  Hemoglobin &gt;= 10 g/dL

          -  Total bilirubin =&lt; 1.5 x upper limit of institutional normal

          -  Alkaline phosphatase =&lt; 1.5 x upper limit of institutional normal

          -  Aspartate aminotransferase (AST) =&lt; 1.5 x upper limit of institutional normal

          -  Alanine aminotransferase (ALT) =&lt; 1.5 x upper limit of institutional normal

          -  Serum creatinine within 1.5 x upper limit of institutional normal

          -  Sodium 135-144 mmol/L (inclusive)

          -  Potassium 3.2-4.8 mmol/L (inclusive)

          -  Participants will be required to use a medically-approved method of birth control or
             abstinence if their sexual partner is of child-bearing potential

          -  Participants must be willing to forego foods, beverages and supplements containing
             pomegranate for the duration of the study

          -  Ability to understand, and the willingness to sign, a written informed consent
             document

        Exclusion Criteria:

          -  Any prior surgery to the prostate within 30 days of baseline procedures; NOTE:
             Biopsies are not considered surgeries

          -  Evidence of other cancer(s) (excluding non-melanoma skin cancer) within last 5 years

          -  Prior pelvic radiation for any reason

          -  Subjects taking nonsteroidal anti-inflammatory drugs (NSAIDS) on a regularly
             scheduled basis, except for cardioprotective aspirin (81mg); subjects may take
             acetaminophen if they have pain

          -  Participants cannot be taking 5-Î±-reductase inhibitors while on study nor within 6
             months of pre-study prostate biopsy

          -  Participants may not be taking carbamazepine (Tegretol)

          -  Participants may not be receiving any other investigational agents

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to PFE

          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, or psychiatric illness/social situations that would limit compliance with
             study requirements

          -  Any significant cardiac event(s) within the 12 months prior to registration, such as
             episode(s) of symptomatic congestive heart failure, myocardial infarction, unstable
             angina pectoris or persistent, stable angina pectoris, or cardiac arrhythmia
             requiring medication
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tracy Downs</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Wisconsin Hospital and Clinics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James E. Bryant</last_name>
      <phone>205-996-2613</phone>
      <email>jebryant@uabmc.edu</email>
    </contact>
    <investigator>
      <last_name>James E. Bryant</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lahey Hospital and Medical Center</name>
      <address>
        <city>Burlington</city>
        <state>Massachusetts</state>
        <zip>01805</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jason R. Gee</last_name>
      <phone>718-744-8334</phone>
      <email>jason.r.gee@lahey.org</email>
    </contact>
    <investigator>
      <last_name>Jason R. Gee</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Masonic Cancer Center, University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Badrinath R. Konety</last_name>
      <phone>612-626-8599</phone>
      <email>brkonety@umn.edu</email>
    </contact>
    <investigator>
      <last_name>Badrinath R. Konety</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Rochester</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Edward M. Messing</last_name>
      <phone>585-275-3345</phone>
      <email>edward_messing@urmc.rochester.edu</email>
    </contact>
    <investigator>
      <last_name>Edward M. Messing</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Urology San Antonio Research PA</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel R. Saltzstein</last_name>
      <phone>210-617-4116</phone>
      <email>dsaltzstein@satx.rr.com</email>
    </contact>
    <investigator>
      <last_name>Daniel R. Saltzstein</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin Hospital and Clinics</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tracy M. Downs</last_name>
      <phone>608-262-2369</phone>
      <email>downs@urology.wisc.edu</email>
    </contact>
    <investigator>
      <last_name>Tracy M. Downs</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 19, 2014</lastchanged_date>
  <firstreceived_date>March 20, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
